In Saudi Arabia, the Hevolution Foundation is Reshaping Ageing Research

By Staff Writer

September 17, 2024

Introduction

In a phase where global life expectancy is projected to rise from 73.6 years in 2022 to 78.1 years by 2050, the focus is shifting from merely extending lifespan to enhancing healthspan – the number of years lived in good health. At the forefront of this paradigm shift is Hevolution Foundation, a non-profit organisation based in Riyadh, Saudi Arabia. With an unprecedented commitment of up to $1 billion annually, Hevolution Foundation is transforming the field of ageing research.

The Global Economics of Ageing

The demographic shifts on the horizon underscore the urgency of Hevolution’s mission. By 2050, the population over 60 years worldwide will double to 2 billion. This means one-fifth of the world’s population will exceed this age threshold. Most importantly, low and middle-income countries will house 80% of this older population. This presents a unique challenge to their healthcare systems and economies. 

In the United States alone, the Centers for Disease Control and Prevention estimates annual costs of $305 billion for Alzheimer’s disease, $237 billion for diabetes, $216 billion for heart disease and stroke, and $140 billion for arthritis. These figures exclude broader economic impacts and lost productivity.

Hevolution’s Impact on Ageing Healthcare

In just two years, Hevolution has committed approximately $400 million toward the geroscience field, becoming the largest philanthropic funder in this space globally. This influx of capital is addressing a critical gap in the research ecosystem.

Hevolution’s investments span a wide range, from supporting individual researchers to funding major institutions. For example, $27 million has been allocated for nine innovative projects deemed meritorious by the U.S. National Institute on Aging. These projects explore areas such as mitochondrial dysfunction and epigenetics. Moreover, $20 million has been granted to the Albert Einstein College of Medicine for research on senescence and ageing. Northwestern University received $32.4 million for studies on proteostasis in ageing, and The Buck Institute for Research on Aging secured $21 million for a multi-year partnership.

Connecting and Collaborating

Beyond direct research funding, Hevolution is also working to expand the field’s talent pool. Initiatives like the $5.2 million grant program to create the first cohort of ageing researchers in Saudi Arabia and the $5 million Postdoctoral Training in Geroscience program aim to nurture the next generation of geroscience experts.

The foundation strategically invested in biotech companies such as Aeovian Pharmaceuticals. It contributed $20 million to promote therapies that target the mTORC1 biological pathway. Hevolution has initiated a partnership with XPRIZE. They launched the Healthspan global competition with a $101 million prize. This competition, one of the largest in XPRIZE history, challenges teams to create therapeutics targeting biological ageing. 

Ensuring Equitable Access

The scientific advancements in ageing research raise important ethical questions about access and affordability. Hevolution’s commitment to accessibility is integral to its investment strategy. Every investment includes a condition around scalability. This focus on democratising healthspan technologies is crucial for benefiting all of humanity, not just those in wealthy nations.

New Horizons and Opportunities

Despite the progress made, significant hurdles remain. The regulatory landscape for ageing-related treatments is still evolving, with no clear pathway for approval of interventions that target ageing itself rather than specific diseases. Hevolution is actively engaging with policymakers to address these challenges and continues to advocate for a more supportive regulatory environment that recognises the clinical validity of ‘pre-disease’ states and new biomarkers. Saudi Arabia has an emerging centre of expertise, and others around the world are following suit.

Conclusion

The Hevolution Foundation’s ambitious mission reveals its broader implications. Extending healthspan isn’t just a scientific pursuit, but a societal necessity with vast economic, ethical, and social impacts. For investors, policymakers, and the general public, the message is clear. We no longer have to accept ageing as an unchangeable fact of life. Instead, it’s a scientific innovation frontier with huge potential for impact.

Reference url

Recent Posts

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.